Delcath Systems

HEPZATO Kit Use And Emerging Markets Will Widen Oncology Reach

AnalystHighTarget

Not Invested

Consensus Narrative from 6 Analysts

Published

25 Aug 25

Updated

25 Aug 25

AnalystHighTarget's Fair Value

US$30.83

63.9% undervalued

25 Aug

US$11.12

5.5%

5.3%

5.5%

5.3%

Author's Valuation

US$30.8

63.9% undervalued

AnalystHighTarget Fair Value

Narrative

Updates0

AnalystHighTarget Fair Value

US$30.8

63.9% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

23.23%

Medical Equipment revenue growth rate

0.45%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

7.47%

Calculation

US$102.48m

Earnings '28

17.11x

PE Ratio '28

US$1.75b

Market Cap '28

US$1.75b

Market Cap '28

45.81m

No. shares '28

US$38.28

Share Price '28

US$38.28 Share Price '28

Discounted to 2025 @ 7.47% p.a.

US$30.83

Fair Value '25